Dendrimers as drug carriers: Applications in different routes of drug administration

Journal of Pharmaceutical Sciences

Volumn 97, Issue 1, 2008, Pages 123-143

  Cheng, Yiyun ^a,b   Xu, Zhenhua ^b   Ma, Minglu ^b   Xu, Tongwen ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Administration routes; Dendrimer; Intravenous; Ocular; Oral; PAMAM; PPI; Transdermal; Transmucosal

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BORON; CHLORAMPHENICOL ACETYLTRANSFERASE; CISPLATIN; COLLAGEN; DENDRIMER; DIFLUNISAL; DNA; FLUOROURACIL; FLURBIPROFEN; GLUCOSAMINE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MACROGOL; MELAMINE; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; POLYAMIDOAMINE; POLYESTER; PORPHYRIN; PRIMAQUINE DERIVATIVE; PRIMAQUINE PHOSPHATE; PROPRANOLOL DERIVATIVE; STARBURST; TAMSULOSIN; TROPICAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; COMPLEX FORMATION; COVALENT BOND; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION; GEL ELECTROPHORESIS; GEL PERMEATION CHROMATOGRAPHY; GENETIC TRANSFECTION; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; NANOANALYSIS; NEUTRON CAPTURE THERAPY; NONHUMAN; PHLEBITIS; REVIEW; SIDE EFFECT; TRANSMISSION ELECTRON MICROSCOPY; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE;

EID: 38349134916     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21079     Document Type: Article

References (127)

1. Tomalia DA, Baker H, Dewald J, Hall M, G K, Martin S, Roeck J, Ryder J, Smith P. 1985. A new class of polymers: Starburst-dendritic macromolecules. Polym J 17:117-132.
2. Tomalia DA, Naylor AM, Goddard WA. 1990. Starburst dendrimers: Molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl 29:138.
3. Al-Jamal KT, Ramaswamy C, Florence AT. 2005. Supramolecular structures from dendrons and dendrimers. Adv Drug Deliv Rev 57:2238-2270.
4. Elemans JAAW, Boerakker MJ, Holder SJ, Rowan AE, Cho W-D, Percec V, Nolte RJM. 2002. Supramolecular chemistry and self-assembly special feature: Plastic- and liquid-crystalline architectures from dendritic receptor molecules. PNAS 99: 5093-5098.
5. Credi A, Ribera BF, Venturi M. 2004. From supramolecular electrochemistry to molecular-level devices. Electrochim Acta 49:3865-3872.
6. Momotake A, Arai T. 2004. Photochemistry and photophysics of stilbene dendrimers and related compounds. J Photochem Photobiol C: Photochem Rev 5:1-25.
7. Wu H, Liu Z, Wang X, Zhao B, Zhang J, Li C. 2006. Preparation of hollow capsule-stabilized gold nanoparticles through the encapsulation of the dendrimer. J Colloid Interface Sci 302:142-148.
8. Love CS, Ashworth I, Brennan C, Chechik V, Smith DK. 2006. Dendron-protected Au nanoparticles - Effect of dendritic structure on chemical stability. J Colloid Interface Sci 302:178-186.
9. Yan S, Zhou Z, Zhang F, Yang S, Yang L, Yu X. 2006. Effect of anionic PAMAM with amido groups starburst dendrimers on the crystallization of Ca10(PO4)6(OH)2 by hydrothermal method. Mater Chem Phys 99:164-169.
10. Xu Y, Zhao D. 2005. Removal of copper from contaminated soil by use of poly(amidoamine) dendrimers. Environ Sci Technol 39:2369-2375.
11. Arkas M, Allabashi R, Tsiourvas D, Mattausch EM, Perfler R. 2006. Organic/Inorganic Hybrid Filters Based on Dendritic and Cyclodextrin "Nanosponges" for the Removal of Organic Pollutants from Water. Environ Sci Technol 40:2771-2777.
12. 2 groups. Environ Sci Technol 39:1366-1377.
13. Cheng YY, Fu RQ, Xu TW. 2005. Polyamidoamine (PAMAM) dendrimers in dye decolorisation. Polym Polym Composites 13:831-833.
14. Cheng YY, Yang JP. 2005. Effect of polyamidoamine dendrimers in decolorising triarylmethane dye effluent. Coloration Technology 121:72-75.
15. Sayed-Sweet Y, Hedstrand DM, Spinder R, Tomalia DA. 1997. Hydrophobically modified poly(amidoamine) (PAMAM) dendrimers: Their properties at the air-water interface and use as nanoscopic container molecules. J Mater Chem 7: 1199-1205.
16. Vladimir VT. 1998. Dendritic macromolecules at interfaces. Adv Mater 10:253-257.
17. Karthaus O, Ijoro K, Shimomura M, Hellmann J, Irie M. 1996. Monomolecular layers, of diarylethene-containing dendrimers. Langmuir 12: 6714-6716.
18. Cheng YY, Xu TW, He PS. 2007. Polyamidoamine (PAMAM) dendrimers as curing agents: The optimum PAMAM concentration selected by dynamic torsional vibration method and thermogravimetric analyses. J Appl Polym Sci 103:1430-1434.
19. Cheng YY, Chen DZ, Fu RQ, He PS. 2005. Behavior of polyamidoamine dendrimers as curing agents in bis-phenol A epoxy resin systems. Polym Int 54: 495-499.
20. Lee JJ, Ford WT. 1994. Reactivity of organic anions promoted by a quaternary ammonium ion dendrimer. Macromolecules 27:4632-4634.
21. Mak CC, Cow HF. 1997. Dendritic catalysts: Reactivity and mechanism of the dendritic bis(oxazoline)metal co1228-1230mplex catalyzed Diels-Alder reaction. Macromolecules 30:1228-1230.
22. Bhyrappa P, Young JK, Moore JS, Suslick KS. 1996. Dendrimer- metalloporphyrins: Synthesis and catalysis. J Am Chem Soc 118:5708-5711.
23. Fujita M, Oguro D, Miyazawa M, Oka H, Yamaguchi K, Ogura K. 1995. Self-assembly of ten molecules into nanometre-sized organic host frameworks. Nature 378:469-471.
24. Svenson S, Tomalia DA. 2005. Dendrimers in biomedical applications - Reflections on the field. Adv Drug Deliv Rev 57:2106-2129.
25. D'Emanuele A, Attwood D. 2005. Dendrimer-drug interactions. Adv Drug Deliv Rev 57:2147-2162.
26. Aulenta F, Hayes W, Rannard S. 2003. Dendrimers: A new class of nanoscopic containers and delivery devices. Eur Polym J 39:1741-1771.
27. Patri AK, Majoros IJ, Baker J, Jr. 2002. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 6:466-471.
28. Florence AT. 2005. Preface - Dendrimers: A versatile targeting platform. Adv Drug Deliv Rev 57: 2104-2105.
29. Dufes C, Uchegbu IF, Schatzlein AG. 2005. Dendrimers in gene delivery. Adv Drug Deliv Rev 57: 2177-2202.
30. Kim J, Choi J, Nam K, Lee M, Park J, Lee J. 2006. Enhanced transfection of primary cortical cultures using arginine-grafted PAMAM dendrimer, PAMAM-Arg. J Control Release 114:110-117.
31. Bayele HK, Ramaswamy C, Wilderspin AF, Srai KS, Toth I, Florence AT. 2006. Protein transduction by lipidic peptide dendrimers. J Pharm Sci 95: 1227-1237.
32. Esfand R, Tomalia DA. 2001. Poly(amidoamine) (PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications. Drug Discov Today 6:427-436.
33. Gillies ER, Frechet JMJ. 2005. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 10:35-43.
34. Jansen JFGA, Debrabandervandenberg EMM, Meijer EW. 1994. Encapsulation of guest molecules into a dentritic box. Science 266:1226-1229.
35. Milhem OM, Myles C, McKeown NB, Attwood D, D'Emanuele A. 2000. Polyamidoamine Starburst (R) dendrimers as solubility enhancers. Int J Pharm 197:239-241.
36. Cheng YY, Xu TW. 2005. Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem 40:1188-1192.
37. Yang H, Morris JJ, Lopina ST. 2004. Polyethylene glycol-polyamidoamine dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J Colloid Interface Sci 273:148-154.
38. Caminade A, Laurent R, Majorai J. 2005. Characterization of dendrimers. Adv Drug Deliv Rev 57:2130-2146.
39. Tomalia D, Dewald J, Hall M, Martin S, Smith P. 1984. Reprints of the 1st SPSJ International Polymer Conference. Soc Polym Sci 65.
40. Hawker CJ, Frechet JMJ. 1990. Preparation of polymers with controlled molecular architecture - A new convergent approach to dendritic macromolecules. J Am Chem Soc 112:7638-7647.
41. Tomalia DA. 2005. Birth of a new macromolecular architecture: Dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Polym Sci 30:294-324.
42. Kim YK, Zimmerman SC. 1998. Applications of dendrimers in bio-organic chemistry. Curr Opin Chem Biol 2:733-742.
43. Jackson CL, Chanzy HD, Booy FP, Drake BJ, Tomalia DA, Bauer BJ, Amis EJ. 1998. Visualization of dendrimer molecules by transmission electron microscopy (TEM): Staining methods and Cryo-TEM of vitrified solutions. Macromolecules 31:6259-6265.
44. Kallos GJ, Tomalia DA, Hedstrand DM, Zhou SLJ. 1991. Molecular weight determination of a polyamidoamine Starburst polymer by electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 5:383-386.
45. Peterson J, Allikmaa V, Subbi J, Pehk T, Lopp M. 2003. Structural deviations in poly(amidoamine) dendrimers: A MALDI-TOF MS analysis. Eur Polym J 39:33-42.
46. Frechet JMJ, Hawker CJ. 1996. Synthesis and properties of dendrimers and hyperbranched polymers. Compr Polym Sci S2:71-132.
47. Welch P, Muthukumar M. 1998. Tuning the density profile of dendritic polyelectrolytes. Macromolecules 31:5892-5897.
48. Devarakonda B, Hill RA, de Villiers MM. 2004. The effect of PAMAM dendrimer generation size and surface functional group on thenqueous solubility of nifedipine. Int J Pharm 284:133-140.
49. Kojima C, Kono K, Maruyama K, Takagishi T. 2000. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjugate Chem 11:910-917.
50. Cheng YY, Xu TW. 2005. Solubility of nicotinic acid in polyamidoamine dendrimer solutions. Eur J Med Chem 40:1384-1389.
51. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. 2003. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 259:143-160.
52. Chauhan AS, Sridevi S, Chalasani KB, Jain AK, Jain SK, Jain NK, Diwan PV. 2003. Dendrimer-mediated transdermal delivery: Enhanced bioavailability of indomethacin. J Control Release 90:335-343.
53. Cheng YY, Xu TW, Fu RQ. 2005. Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. Eur J Med Chem 40:1390-1393.
54. Ma ML, Cheng YY, Xu ZH, Xu P, Qu HO, Fang YJ, Xu TW, Wen LP. 2006. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem 42: 93-98.
55. Gupta U, Agashe HB, Asthana A, Jain NK. 2006. Dendrimers: Novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules 7:649-658.
56. Malik N, Evagorou EG, Duncan R. 1999. Dendrimer-platinate: A novel approach to cancer chemotherapy. Anticancer Drugs 10:767-776.
57. Majoros IJ, Myc A, Thomas T, Mehta CB, Baker JR. 2006. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality. Biomacromolecules 7: 572-579.
58. Patri AK, Kukowska-Latallo JF, Baker J, Jr. 2005. Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 57:2203-2214.
59. Uhrich K, Cannizzaro S, Langer R, Shakesheff K. 1999. Polymeric systems for controlled drug release. Chem Rev 99:3181-3198.
60. Milhem OM, Mobedi H, Day N, McKeown N, Attwood D. 2001. Development of dendrimer conjugates for drug delivery. Polym Mater Sci Eng 84: 721.
61. Moghimi SM, Bonnemain B. 1999. Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: Applications in lymphoscintigraphy and indirect lymphography. Adv Drug Deliv Rev 37:295-312.
62. Gebbia V, Puozzo C. 2005. Oral versus intravenous vinorelbine: Clinical safety profile. Expert Opin Drug Saf 4:915-928.
63. Markman M. 2003. Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol 4:277-283.
64. Di Venosa G, Casas A, Battah S, Dobbin P, Fukuda H, Macrobert A, Batlle A. 2006. Investigation of a novel dendritic derivative of 5-aminolaevulinic acid for photodynamic therapy. Int J Biochem Cell Biol 38:82-91.
65. Vincent L, Varet J, Pille JY, Bompais H, Opolon P, Maksimenko A, Malvy C, Mirshahi M, Lu H, Soria JPVC, Li H. 2003. Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: In vitro and in vivo studies. Int J Cancer 105:419-429.
66. Vannucci L, Fiserova A, Sadalapure K, Lindhorst TK, Kuldova M, Rossmann P, Horvath O, Kren V, Krist P, Bezouska K, Luptovcova M, Mosca F, Pospisil M. 2003. Effects of N-acetyl-glucosamine-coated glycodendrimers as biological modulators in the B16F10 melanoma model in vivo. Int J Oncol 23:285-296.
67. Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, Fujibayashi Y, Konishi J, Brechbiel MW. 2001. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 7:3606-3612.
68. Wu G, Barth RF, Yang WL, Chatterjee M, Tjarks W, Ciesielski MJ, Fenstermaker RA. 2004. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug Chem 15:185-194.
69. Barth RF, Wu G, Yang WL, Binns PJ, Riley KJ, Patel H, Coderre JA, Tjarks W, Bandyopadhyaya AK, Thirumamagal BTS, Ciesielski MJ, Fenstermaker RA. 2004. Neutron capture therapy of epidermal growth factor (plus) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl Radiat Isot 61:899-903.
70. Yang WL, Barth RF, Adams DM, Ciesielski MJ, Fenstermaker RA, Shukla S, Tjarks W, Caligiuri MA. 2002. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res 62:6552-6558.
71. Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Brechbiel MW, Konishi J. 2000. Intraperitoneal tumor targeting of DNA complexed with polyamidoamine dendrimers or avidin and its imaging in mice. J Nucl Med 41:260P-260P.
72. Duncan R, Izzo L. 2005. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57:2215-2237.
73. Roberts JC, Bhalgat MK, Zera RT. 1996. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst (TM) dendrimers. J Biomed Mater Res 30:53-65.
74. Chen HT, Neerman MF, Parrish AR, Simanek EE. 2004. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J Am Chem Soc 126:10044-10048.
75. De Jesus OLP, Ihre HR, Gagne L, Frechet JMJ, Szoka FC. 2002. Polyester dendritic systems for drug delivery applications: In vitro and in vivo evaluation. Bioconjug Chem 13:453-461.
76. Kukowska-Latallo JF, Candido KA, Cao ZY, Nigavekar SS, Majores IJ, Thomas TP, Balogh LP, Khan MK, Baker JR. 2005. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65:5317-5324.
77. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R. 2000. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of I-125-labelled polyamidoamine dendrimers in vivo. J Control Release 68:299-302.
78. Wilbur DS, Pathare PM, Hamlin DK, Buhler KR, Vessella RL. 1998. Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers. Bioconjug Chem 9:813-825.
79. Okuda T, Kawakami S, Maeie T, Niidome T, Yamashita F, Hashida M. 2006. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J Control Release 114:69-77.
80. Bhadra D, Bhadra S, Jain S, Jain NK. 2003. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 257:111-124.
81. Chauhan AS, Jain NK, Diwan PV, Khopade AJ. 2004. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target 12:575-583.
82. Asthana A, Chauhan AS, Diwan PV, Jain NK. 2005. Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS Pharm Sci Tech 6:E536-542.
83. Bhadra D, Yadav AK, Bhadra S, Jain NK. 2005. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 295:221-233.
84. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, Baker JR. 2005. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem 48:3729-3735.
85. Majoros IJ, Thomas TP, Mehta CB, Baker JR. 2005. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem 48:5892-5899.
86. Barth RF, Adams DM, Soloway AH, Alam F, Darby MV. 1994. Boronated starburst dendrimer monoclonal-antibody immunoconjugates - Evaluation as a potential delivery system for neutron-capture therapy. Bioconjug Chem 5:58-66.
87. Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker JR. 2005. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun 46:5739-5741.
88. Yang WL, Barth RF, Adams DM, Soloway AH. 1997. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res 57:4333-4339.
89. Yang WL, Barth RF, Wu G, Bandyopadhyaya AK, Thirumamagal BTS, Tjarks W, Binns PJ, Riley K, Patel H, Coderre JA. 2004. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas. Appl Radiat Isot 61:981-985.
90. Kukowska-Latallo JF, Chen C, Raczka E, Qunintana A, Rymaszewski M, Baker JR. 2000. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. Hum Gene Ther 11:1385-1395.
91. Kihara F, Arima H, Tsutsumi T, Hirayama F, Uekama K. 2003. In vitro and in vivo gene transfer by an optimized alpha-cyclodextrin conjugate with polyamidoamine dendrimer. Bioconjug Chem 14: 342-350.
92. Wada K, Arima H, Tsutsumi T, Chihara Y, Hattori K, Hirayama F, Uekama K. 2005. Improvement of gene delivery mediated by mannosylated dendrimer/[alpha]- cyclodextrin conjugates. J Control Release 104:397-413.
93. 111In-labeled oligo-DNA with avidin or avidin-dendrimer complex. J Control Release 95:133-141.
94. Dufes C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schatzlein AG. 2005. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res 65:8079-8084.
95. Schatzlein AG, Zinselmeyer BH, Elouzi A, Dufes C, Chim YTA, Roberts CJ, Davies MC, Munro A, Gray AI, Uchegbu IF. 2005. Preferential liver gene expression with polypropylenimine dendrimers. J Control Release 101:247-258.
96. Tack F, Bakker A, Maes S, Dekeyser N, Bruining M, Elissen-Roman C, Janicot M, Brewster M, Janssen HM, Waal BFMD, Fransen PM, Lou X, Meijer EW. 2006. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J Drug Target 14:69-86.
97. Csaba N, Garcia-Fuentes M, Alonso MJ. 2006. The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Deliv 3:463-478.
98. Lambkin I, Pinilla C. 2002. Targeting approaches to oral drug delivery. Expert Opin Biol Ther 2: 67-73.
99. D'Emanuele A, Attwood D, Abu-Rmaileh R. 2003. Dendrimers Encyclopedia Pharm Technol 3:1-21.
100. Sakthivel T, Toth I, Florence AT. 1999. Distribution of a lipidic 2.5 nm diameter dendrimer carrier after oral administration. Int J Pharm 183:0378-5173.
101. Wiwattanapatapee R, Carreno-Gomez B, Malik N, Duncan R. 2000. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: A potential oral delivery system? Pharm Res 17:991-998.
102. Florence AT, Sakthivel T, Toth I. 2000. Oral uptake and translocation of a polylysine dendrimer with a lipid surface. J Control Release 65:253-259.
103. Pantzar N, Lundin S, Wester L, Westrom BR. 1994. Bidirectional small-intestinal permeability in the rat to some common marker molecules in-vitro. Scand J Gastroenterol 29:703-709.
104. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D. 2004. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 95:447-453.
105. Tripathi PK, Khopade AJ, Nagaich S, Shrivastava S, Jain S, Jain NK. 2002 Dendrimer grafts for delivery of 5-fluorouracil. Pharmazie 57:261-264.
106. Man N, Cheng YY, Xu TW, Ding Y, Wang XM, Li ZW, Chen ZC, Huang GY, Shi YY, Wen LP. 2006. Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur J Med Chem 41:670-674.
107. Ramachandran C, Fleisher D. 2000. Transdermal delivery of drugs for the treatment of bone diseases. Adv Drug Deliv Rev 42:197-223.
108. Thomas BJ, Finnin BC. 2004. The transdermal revolution. Drug Discov Today 9:697-703.
109. Kalia YN, Naik A, Garrison J, Guy RH. 2004. Iontophoretic drug delivery. Adv Drug Deliv Rev 56:619-658.
110. Wang ZX, Itoh Y, Hosaka Y, Kobayashi I, Nakano Y, Maeda I, Umeda F, Yamakawa J, Kawase M, Yag K. 2003. Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer. J Biosci Bioeng 95: 541-543.
111. Wang ZX, Yoshiaki I, Yoshifumi H. 2003. Mechanism of enhancement effect of dendrimer on transdermal drug permeation through polyhydroxyalkanoate matrix. J Biosci Bioeng 96:537-540.
112. Cheng YY, Man N, Xu TW. 2006. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J Pharm Sci 96:595-602.
113. Bielinska AU, Yen A, Wu HL, Zahos KM, Sun R, Weiner ND, Baker JR, Jr., Roessler BJ. 2000. Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo. Biomaterials 21:877-887.
114. Myles ME, Neumann DM, Hill JM. 2005. Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 57:2063-2079.
115. Vandamme TF, Brobeck L. 2005. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 102:23-38.
116. Geroski DH, Edelhauser HF. 2001. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 52:37-18.
117. Robinson JR, Mlynek GM. 1995. Bioadhesive and phase-change polymers for ocular drug delivery. Adv Drug Deliv Rev 16:45-50.
118. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. 1998. Ophthalmic drug delivery systems - Recent advances. Prog Retin Eye Res 17:33-58.
119. Vandamme TF. 2002. Microemulsions as ocular drug delivery systems: Recent developments and future challenges. Prog Retin Eye Res 21: 15-34.
120. Shimpi S, Chauhan B, Shimpi P. 2005. Cyclodextrins: Application in different routes of drug administration. Acta Pharm 55:139-156.
121. Loftsson T, Stefansson E. 1997. Effect of cyclodextrins on topical drug delivery to the eye. Drug Dev Ind Pharm 23:473-481.
122. Shaunak S, Thomas S, Gianasi E, Godwin A, Jones E, Teo I, Mireskandari K, Luthert P, Duncan R, Patterson S, Khaw P, Brocchini S. 2004. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 22:977-984.
123. Duan X, Sheardown H. 2006. Dendrimer cross-linked collagen as a corneal tissue engineering scaffold: Mechanical properties and corneal epithelial cell interactions. Biomaterials 27: 4608-4617.
124. Duan X, McLaughlin C, Griffith M, Sheardown H. 2007. Biofunctionalization of collagen for improved biological response: Scaffolds for corneal tissue engineering. Biomaterials 28:78-88.
125. Wimmer N, Marano RJ, Kearns PS, Rakoczy EP, Toth I. 2002. Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides. Bioorg Med Chem Lett 12:2635-2637.
126. Marano RJ, Wimmer N, Kearns PS, Thomas BG, Toth I, Brankov M, Rakoczy PE. 2004. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res 79:525-535.
127. Bernstein DI, Bourne N, Ayisi NK. 2003. Evaluation of formulated dendrimer SPL7013 as a microbicide. Antivirus Res 57:89.